{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:39:45Z","timestamp":1789634385755,"version":"build-2803163510"},"reference-count":16,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,8,1]]},"abstract":"<jats:p>Objective. Indomethacin is used for closing the patent ductus arteriosus in premature infants. Prolonged low-dose indomethacin given over 6 days could potentially improve closure rates because ductal constriction is maintained long enough for more effective anatomic closure. We compared the efficacy of this regimen to conventional dosing in a cohort of very low birth weight infants.<\/jats:p>\n               <jats:p>Methods. In a 2-arm clinical trial, 140 infants were randomized to either conventional dose (0.2 mg\/kg\/dose every 12 hours for 3 doses) or prolonged low-dose indomethacin (0.1 mg\/kg\/dose daily for 6 doses). The primary outcome measure was ductal closure rate, and the secondary outcomes were the need for a second course of treatment, surgical ligation rates, and side effects.<\/jats:p>\n               <jats:p>Results. Ductal closure after 1 course of indomethacin was similar between the 2 groups: 68% for the conventional dose group and 72% for the prolonged low dose (mean difference \u22124%; 95% confidence interval: \u221219% to 11%). The incidence of transient oliguria was higher in the conventional dose group, 31% versus 9%. There was a trend toward more necrotizing enterocolitis in the prolonged low-dose group, 7.0% versus 1.4%.<\/jats:p>\n               <jats:p>Conclusions. There was no difference in efficacy between the 2 dosing regimens. In view of this and with its higher incidence of necrotizing enterocolitis, we do not recommend using prolonged low-dose indomethacin for closing the patent ductus arteriosus in very low birth weight infants.<\/jats:p>","DOI":"10.1542\/peds.112.2.345","type":"journal-article","created":{"date-parts":[[2004,8,14]],"date-time":"2004-08-14T00:43:47Z","timestamp":1092444227000},"page":"345-350","source":"Crossref","is-referenced-by-count":34,"title":["Randomized Trial of Prolonged Low-Dose Versus Conventional-Dose Indomethacin for Treating Patent Ductus Arteriosus in Very Low Birth Weight Infants"],"prefix":"10.1542","volume":"112","author":[{"given":"Jiun","family":"Lee","sequence":"first","affiliation":[{"name":"Departments of Neonatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Samuel","family":"Rajadurai","sequence":"additional","affiliation":[{"name":"Departments of Neonatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keng Wee","family":"Tan","sequence":"additional","affiliation":[{"name":"Departments of Neonatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keng Yean","family":"Wong","sequence":"additional","affiliation":[{"name":"Pediatrics, KK Women\u2019s and Children\u2019s Hospital, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ee Hwee","family":"Wong","sequence":"additional","affiliation":[{"name":"Clinical Trials and Epidemiology Research Unit, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy Yoke Ngan","family":"Leong","sequence":"additional","affiliation":[{"name":"Clinical Trials and Epidemiology Research Unit, Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2003,8,1]]},"reference":[{"key":"2021121003350812600_R1","doi-asserted-by":"crossref","unstructured":"Gersony WM, Peckham GJ, Ellison RC, Miettinen OS, Nadas AS. Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr.1983;102:895\u2013906","DOI":"10.1016\/S0022-3476(83)80022-5"},{"key":"2021121003350812600_R2","doi-asserted-by":"crossref","unstructured":"Hammerman C. Patent ductus arteriosus: clinical relevance of prostaglandins and prostaglandin inhibitors in PDA pathophysiology and treatment. Clin Perinatol.1995;22:457\u2013479","DOI":"10.1016\/S0095-5108(18)30293-8"},{"key":"2021121003350812600_R3","doi-asserted-by":"crossref","unstructured":"Clyman RI, Chan CY, Mauray F, et al. Permanent anatomic closure of the ductus arteriosus in newborn baboons: the roles of postnatal constriction, hypoxia, and gestation. Pediatr Res.1999;45:19\u201329","DOI":"10.1203\/00006450-199901000-00005"},{"key":"2021121003350812600_R4","doi-asserted-by":"crossref","unstructured":"Rennie JM, Cooke RW. Prolonged low dose indomethacin for persistent ductus arteriosus of prematurity. Arch Dis Child.1991;66:55\u201358","DOI":"10.1136\/adc.66.1_Spec_No.55"},{"key":"2021121003350812600_R5","doi-asserted-by":"crossref","unstructured":"Hammerman C, Aramburo MJ. Prolonged indomethacin therapy for the prevention of recurrences of patent ductus arteriosus. J Pediatr.1990;117:771\u2013776","DOI":"10.1016\/S0022-3476(05)83342-6"},{"key":"2021121003350812600_R6","doi-asserted-by":"crossref","unstructured":"Tammela O, Ojala R, Iivainen T, et al. Short versus prolonged indomethacin therapy for patent ductus arteriosus in preterm infants. J Pediatr.1999;134:552\u2013557","DOI":"10.1016\/S0022-3476(99)70239-8"},{"key":"2021121003350812600_R7","doi-asserted-by":"crossref","unstructured":"Clyman RI. Recommendations for the postnatal use of indomethacin: an analysis of four separate treatment strategies. J Pediatr.1996;128:601\u2013607","DOI":"10.1016\/S0022-3476(96)80123-5"},{"key":"2021121003350812600_R8","doi-asserted-by":"crossref","unstructured":"Kluckow M, Evans N. Early echocardiographic prediction of symptomatic patent ductus arteriosus in preterm infants undergoing mechanical ventilation. J Pediatr.1995;127:774\u2013779","DOI":"10.1016\/S0022-3476(95)70172-9"},{"key":"2021121003350812600_R9","doi-asserted-by":"crossref","unstructured":"Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am.1986;33:179\u2013201","DOI":"10.1016\/S0031-3955(16)34975-6"},{"key":"2021121003350812600_R10","unstructured":"Altman DG, Machin D, Bryant TN, Gardner MJ, eds. Statistics With Confidence. 2nd ed. London, United Kingdom: British Medical Journal Books; 2000"},{"key":"2021121003350812600_R11","doi-asserted-by":"crossref","unstructured":"Seidner S, Chen Y, Oprysko P, et al. Combined prostaglandin and nitric oxide inhibition produces anatomic remodelling and closure of the ductus arteriosus in the premature newborn baboon. Pediatr Res.2001;50:365\u2013373","DOI":"10.1203\/00006450-200109000-00012"},{"key":"2021121003350812600_R12","doi-asserted-by":"crossref","unstructured":"Rennie JM, Doyle J, Cooke RW. Early administration of indomethacin to preterm infants. Arch Dis Child.1986;61:233\u2013238","DOI":"10.1136\/adc.61.3.233"},{"key":"2021121003350812600_R13","doi-asserted-by":"crossref","unstructured":"Ojala R, Ala-Houhala M, Ahonen S, et al. Renal follow up of premature infants with and without perinatal indomethacin exposure. Arch Dis Child Fetal Neonatal Ed.2001;84:F28\u2013F33","DOI":"10.1136\/fn.84.1.F28"},{"key":"2021121003350812600_R14","doi-asserted-by":"crossref","unstructured":"Meyers R, Alpan G, Lin E, Clyman R. Patent ductus arteriosus, indomethacin, and intestinal distension: effects on intestinal blood flow and oxygen consumption. Pediatr Res.1991;29:569\u2013574","DOI":"10.1203\/00006450-199106010-00010"},{"key":"2021121003350812600_R15","doi-asserted-by":"crossref","unstructured":"Rajadurai VS, Yu VYH. Intravenous indomethacin therapy in preterm neonates with patent ductus arteriosus. J Pediatr Child Health.1991;27:370\u2013375","DOI":"10.1111\/j.1440-1754.1991.tb00422.x"},{"key":"2021121003350812600_R16","doi-asserted-by":"crossref","unstructured":"Schmidt B, Davis P, Moddemann D, et al. Long-term effects of indomethacin prophylaxis in extremely low birthweight infants. N Engl J Med.2001;344:1966\u20131972","DOI":"10.1056\/NEJM200106283442602"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/112\/2\/345\/1002321\/pe0803000345.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/112\/2\/345\/1002321\/pe0803000345.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T10:27:19Z","timestamp":1639132039000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/112\/2\/345\/63287\/Randomized-Trial-of-Prolonged-Low-Dose-Versus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,8,1]]},"references-count":16,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2003,8,1]]},"published-print":{"date-parts":[[2003,8,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.112.2.345","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,8,1]]}}}